SK bioscience (302440) Fundamentals 2026 — Revenue Analysis | SniperIQ
SK bioscience (302440) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩2.57T, trading at ₩32750.00 on the KSC. This SniperIQ fundamentals page covers SK bioscience's valuation, profitability (net margin -12.3%), revenue (₩651.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is SK bioscience's market cap?
SK bioscience (302440) has a market capitalization of approximately ₩2.57T, trading at ₩32750.00 on the KSC. Market cap moves with the live share price.
What is SK bioscience's P/E ratio?
SK bioscience's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is SK bioscience?
SK bioscience runs a net profit margin of -12.3%, a gross margin of 6.4%, and an operating margin of -25.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does SK bioscience generate?
SK bioscience reported revenue of ₩651.4B for fiscal year 2025, with net income of -₩56.2B and earnings per share (EPS) of -718.26. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does SK bioscience pay a dividend?
SK bioscience does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is SK bioscience financially healthy?
SK bioscience carries a debt-to-equity ratio of 0.30x and a current ratio of 4.04x, with a market beta of 0.88. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is SK bioscience a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For SK bioscience (302440) the key facts are: market cap ₩2.57T, revenue ₩651.4B, 52-week range 32700-61300. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track SK bioscience's full fundamentals live
Get SK bioscience's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.